United States Molecular Diagnostics Market to Reach US$ 11.157 Billion by 2033 | CAGR 5.8% | North America leads with 40% share |Key players - Roche, Abbott, Thermo Fisher Scientific, QIAGEN

Leander, Texas and Tokyo, Japan - Feb.3.2026
Global Molecular Diagnostics Market reached US$21.01 billion in 2024 and is expected to reach US$37.19 billion by 2033, growing at a CAGR of 5.8% during the forecast period 2025-2033, according to DataM Intelligence report.

The market is driven by the rising prevalence of infectious and genetic diseases and the need for rapid, accurate diagnostic solutions. Techniques such as PCR, next-generation sequencing, and microarray analysis dominate adoption. Hospitals, diagnostic laboratories, and research institutions are primary end-users. Technological advancements, increasing government healthcare initiatives, and growing demand for personalized medicine fuel market growth.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/molecular-diagnostics-market?praveen

Molecular Diagnostics Market: Competitive Intelligence
Roche, Abbott, Thermo Fisher Scientific, QIAGEN, Illumina, Siemens Healthineers, and Hologic

The Molecular Diagnostics Market is experiencing rapid growth as healthcare systems increasingly adopt precision medicine, early disease detection, and personalized treatment strategies. Leading companies such as Roche, Abbott, Thermo Fisher Scientific, QIAGEN, Illumina, Siemens Healthineers, and Hologic are driving the market by providing advanced diagnostic platforms, assays, reagents, and sequencing technologies. Their solutions enable accurate detection of infectious diseases, genetic disorders, cancer biomarkers, and other molecular targets, supporting clinical decision-making and improving patient outcomes.

The competitive strength of the Molecular Diagnostics Market lies in the combination of technological innovation, global reach, and regulatory expertise. Roche, Abbott, and Thermo Fisher lead with comprehensive molecular testing platforms, high-throughput automation, and integrated laboratory solutions. QIAGEN and Illumina focus on next-generation sequencing, sample preparation, and genomic analysis, enabling precision diagnostics and research applications. Siemens Healthineers and Hologic provide clinical diagnostics, imaging integration, and point-of-care molecular solutions, enhancing accessibility and workflow efficiency. Together, these companies create a powerful ecosystem that accelerates innovation, supports diverse clinical needs, and positions the Molecular Diagnostics Market as a cornerstone of modern healthcare and personalized medicine.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/molecular-diagnostics-market?praveen

Fund Raisings
✅ January 2026 - Illumina, Inc. (United States)
Illumina secured strategic investment to expand its next-generation sequencing (NGS) and molecular diagnostic platforms. The funding supports advanced genomic testing, precision medicine applications, and global market expansion.

✅ December 2025 - QIAGEN N.V. (Netherlands)
QIAGEN raised growth capital to strengthen its molecular diagnostics portfolio for infectious diseases, oncology, and genetic testing. The investment focuses on automated workflows, rapid testing solutions, and AI-driven data analysis.

✅ November 2025 - Thermo Fisher Scientific (United States)
Thermo Fisher attracted fresh investment to advance its molecular diagnostic assays and instrumentation. The funding supports development of multiplex testing, high-throughput platforms, and integration with clinical laboratories.

✅ October 2025 - Roche Diagnostics (Switzerland)
Roche Diagnostics secured capital to enhance its molecular diagnostic solutions, including PCR and liquid biopsy assays. The funding emphasizes precision healthcare, real-time monitoring, and early disease detection.

✅ September 2025 - BioMérieux (France)
BioMérieux raised funding to expand molecular diagnostic kits and automated systems for microbiology and infectious disease detection. The investment focuses on rapid testing, point-of-care solutions, and global deployment.

Product Launches & Strategic Partnerships
✅ January 2026 - Roche Diagnostics (Switzerland / Global)
Roche launched a new molecular diagnostic platform for rapid detection of infectious diseases and genetic markers. The system integrates high-throughput PCR and AI-driven data analysis to enhance diagnostic accuracy and speed.

✅ December 2025 - Thermo Fisher Scientific (United States / Global)
Thermo Fisher introduced advanced molecular testing kits and automated workflows for clinical laboratories. The solutions support precision medicine, oncology, and infectious disease testing with improved efficiency and reliability.

✅ October 2025 - QIAGEN (Germany / Global)
QIAGEN expanded its molecular diagnostics portfolio with next-generation sequencing (NGS) panels and companion diagnostic assays. The products focus on personalized medicine, early disease detection, and biomarker-driven therapies.

✅ August 2025 - Abbott Laboratories (United States / Global)
Abbott partnered with healthcare providers to deploy point-of-care molecular diagnostic solutions for rapid infectious disease screening. The collaboration emphasizes accessibility, faster turnaround times, and improved patient outcomes.

M & A
✅ January 2026 - Roche Diagnostics (Switzerland)
Roche Diagnostics acquired a molecular assay startup to enhance its diagnostic testing capabilities. The acquisition strengthens Roche's portfolio in PCR-based tests, next-generation sequencing, and precision diagnostics for infectious and genetic diseases.

✅ December 2025 - Thermo Fisher Scientific (United States)
Thermo Fisher expanded its molecular diagnostics offerings through the acquisition of a digital PCR and AI-driven diagnostic solutions company. The deal accelerates innovation in high-sensitivity molecular testing and laboratory automation.

✅ October 2025 - Qiagen N.V. (Netherlands)
Qiagen completed a strategic acquisition of a molecular diagnostics platform focused on oncology and rare disease testing. The acquisition reinforces Qiagen's position in personalized medicine and advanced diagnostic workflows.

Segments Covered in the Molecular Diagnostics Market:
By Product
The market is segmented into Reagents & Kits 45%, Instruments 35%, and Software & Services 20%. Reagents and kits dominate due to recurring consumption in labs and hospitals for various tests, while instruments are essential for high-throughput and precise diagnostics. Software and services are growing for data analysis, cloud-based reporting, and laboratory automation.

By Technology
Technologies include PCR (Polymerase Chain Reaction) 50%, Next-Generation Sequencing (NGS) 20%, Microarrays 10%, Isothermal Amplification 10%, and Others 10%. PCR leads adoption due to accuracy, versatility, and cost-effectiveness, while NGS and microarrays are expanding in genomics, personalized medicine, and research applications.

By Application
Applications include Infectious Diseases 40%, Oncology 25%, Genetic Disorders 20%, and Others (Cardiovascular, Neurological) 15%. Infectious diseases dominate due to the need for rapid and accurate pathogen detection, while oncology and genetic disorder testing are growing with the rise of precision medicine.

By End-User
End-users comprise Hospitals & Clinics 50%, Diagnostic Laboratories 30%, Research & Academic Institutes 15%, and Others 5%. Hospitals lead due to high patient volumes and routine testing, while diagnostic labs and research institutes are expanding with specialized molecular testing and genomics research.

Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=molecular-diagnostics-market?praveen

Regional Analysis
North America - 40% Share
North America leads with around 40% share, driven by advanced healthcare infrastructure, high adoption of molecular testing technologies, and strong R&D in genomics and personalized medicine. The U.S. dominates with applications in oncology, infectious diseases, genetic testing, and COVID-19 diagnostics.

Europe - 28% Share
Europe accounts for approximately 28% share, supported by increasing demand for early disease detection, government funding, and advanced laboratory facilities. Germany, the UK, France, and Italy are key markets for PCR, NGS, and companion diagnostics.

Asia Pacific - 22% Share
Asia Pacific holds nearly 22% share due to growing healthcare expenditure, rising prevalence of chronic and infectious diseases, and expanding diagnostic infrastructure. China, India, Japan, and South Korea are driving adoption of molecular diagnostics in hospitals, clinics, and research labs.

Latin America - 6% Share
Latin America represents about 6% share, fueled by increasing awareness, improving healthcare infrastructure, and rising government initiatives in diagnostics. Brazil, Mexico, and Argentina are emerging markets for molecular tests, particularly in infectious disease detection and oncology.

Middle East & Africa - 4% Share
Middle East & Africa holds around 4% share, with growth supported by investments in healthcare infrastructure, rising disease prevalence, and adoption of advanced diagnostics. GCC countries, South Africa, and Egypt are gradually expanding molecular diagnostic capabilities.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?praveen

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.